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A large body of information on the HIV-1 
gp120 envelope (Env) glycoprotein variable loop 
domains 1 and 2 (V1 and V2) has accumulated 
over the years. Neither domain is absolutely nec-
essary for the virus. Deletion of either or both 
loops has been shown to be tolerable in the 
context of specific virus strains and can yield 
replication-competent viruses (Wyatt et al., 
1993, 1995; Cao et al., 1997; Stamatatos and 
Cheng-Mayer, 1998; Stamatatos et al., 1998; 
Saunders et al., 2005; Laakso et al., 2007; Bontjer 
et al., 2009). Although length polymorphism 
and the changing glycosylation pattern of the 
V1V2 domain during disease progression have 
long been appreciated (Palmer et al., 1996; 
Chackerian et al., 1997; Fox et al., 1997; Shioda 
et al., 1997; Masciotra et al., 2002; Kitrinos et al., 
2003; Chohan et al., 2005; Sagar et al., 2006; 
Harrington et al., 2007), uncertainty prevails to 
date on which selective forces drive V1V2 evo-
lution. To what extent virus quasispecies with 
decreased V1V2 length and glycosylation are 
preferentially transmitted or have a selective ad-
vantage in early infection is not fully under-
stood (Derdeyn et al., 2004; Ritola et al., 2004; 
Frost et al., 2005; Liu et al., 2008b) and neither 
are the precise roles of the V1V2 domain in 
viral attachment and cell–cell spread (Pastore 
et al., 2006; Sagar et al., 2006; Arthos et al., 2008; 
Cicala et al., 2009). However, the profound in-
fluence of the V1V2 domain on the virus’ sus-
ceptibility to neutralization is well documented 
as deletions and mutations within the V1 and 
V2 loop (especially those that affect glycosylation 
sites) were found to increase sensitivity to neutral-
izing antibodies (Cao et al., 1997; Chackerian 
et al., 1997; Fox et al., 1997; Morikita et al., 
1997; Stamatatos and Cheng-Mayer, 1998; Ly and 
Stamatatos, 2000; Losman et al., 2001; Johnson 
et al., 2003; Cole et al., 2004; Pinter et al., 2004; 
CORRESPONDENCE  
Alexandra Trkola: 
trkola.alexandra@virology.uzh.ch
Abbreviations used: CD4bs, 
CD4 binding site; CD4i,  
CD4 induced; cryo-ET, cryo-
electron tomography; Env, 
envelope; MFI, mean  
fluorescent intensity.
A. Krarup, C. Magnus, and O.F. Brandenberg contributed 
equally to this paper.
Interaction of the gp120 V1V2 loop  
with a neighboring gp120 unit shields  
the HIV envelope trimer against  
cross-neutralizing antibodies
Peter Rusert,1 Anders Krarup,1 Carsten Magnus,4 Oliver F. Brandenberg,1,2 
Jacqueline Weber,1 Anna-Katharina Ehlert,1 Roland R. Regoes,4  
Huldrych F. Günthard,3 and Alexandra Trkola1
1Institute of Medical Virology; 2PhD Program in Microbiology and Immunology; and 3Division of Infectious Diseases  
and Hospital Epidemiology, University Hospital Zurich; University of Zurich, 8006 Zurich, Switzerland
4Institute of Integrative Biology, Swiss Federal Institute of Technology Zurich, 8092 Zurich, Switzerland
The HIV-1 envelope trimer adopts a quaternary conformation that effectively shields 
neutralization-sensitive domains and thus represents a major obstacle for natural and 
vaccine-elicited antibody responses. By using a structure–function analysis based on a 
specifically devised mathematical model, we demonstrate in this study that protection  
from neutralization is enforced by intersubunit contact between the variable loops 1 and 2 
(V1V2) and domains of neighboring gp120 subunits in the trimer encompassing the  
V3 loop. Our data are consistent with an interaction of the V1V2 and V3 loop at the spike 
apex as proposed by cryoelectron tomography experiments. By defining the orientation of 
the V1V2 loop within the trimer toward the neighboring gp120 subunit’s V3 loop, our data 
close an important gap in the understanding of the architecture of the trimeric spike. 
Knowledge on how the V1V2 barrier functions in the context of the trimer to mask con-
served epitopes on gp120 may aid future vaccine design.
© 2011 Rusert et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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the V1V2 and V3 loop (Kwong et al., 2000; Chen et al., 
2005). Thus, V1V2 domains could potentially protect the 
V3 loop on neighboring (adjacent) gp120 subunits within the 
Env trimer. In recent years, cryoelectron tomography (cryo-ET) 
studies have brought important insights on the three-dimensional 
organization of the Env spike (Zanetti et al., 2006; Zhu et al., 
2006; Liu et al., 2008a; White et al., 2010; Wu et al., 2010). 
Although cryo-ET yet lacks the resolution to precisely and 
unambiguously define intersubunit contact areas within the 
native spike, data available to date suggest that heterotypic 
loop interactions of the V1V2 and V3 loops may indeed occur 
in the apex of the spike (Liu et al., 2008a; White et al., 2010; 
Wu et al., 2010). These findings further support the notion 
that V1V2 shielding may indeed involve an inter- or intra-
subunit interaction with the V3 loop.
RESULTS
High titered cross-reactive plasma antibody response  
is efficiently shielded by the V1V2 loop
Past investigations on the influence of the V1V2 loop on steer-
ing neutralization activity have been restricted to few, mostly 
highly neutralization-sensitive isolates (HxB2, LAI, SF162, 
R3A, and YU-2; Wyatt et al., 1993, 1995; Cao et al., 1997; 
Stamatatos and Cheng-Mayer, 1998; Stamatatos et al., 1998; 
Sullivan et al., 1998; Saunders et al., 2005; Laakso et al., 
2007; Bontjer et al., 2009) and thus left a definite verdict on 
the potency of the V1V2 loop shielding effect against primary 
viruses pending. In this study, we generated a panel of six 
infection-competent V1V2 loop–deleted Env’s of tier 1 (NL4-3 
and SF162), tier 2 (JR-FL*, RHPA, and REJO), and tier 3 
(ZA110.c10.14) subtype B isolates by inserting the linker se-
quence Asp-Ala-Gly (DAG) as described previously (Fig. S1 A 
and Table S1; Bontjer et al., 2009). WT and matching V1V2-
deleted viruses were then compared for sensitivity to neutraliza-
tion by plasma samples from 83 individuals with chronic 
HIV infection from different genetic subtypes (Fig. 1 A 
and Tables S3 and S4). In the absence of the shield-
ing effect of the V1V2, potent cross-neutralization 
activity was detected in all probed patient plasma sam-
ples with some neutralization titers exceeding those of 
WT viruses by more than four orders of magnitude. 
Pugach et al., 2004; Krachmarov et al., 2005, 2006; Saunders 
et al., 2005; Sagar et al., 2006; Shibata et al., 2007; Ching et al., 
2008). Collectively, these studies suggest that the V1V2 loop 
can both function as a direct target for neutralizing antibodies 
elicited in vivo and shield distant neutralization-sensitive do-
mains on the viral Env such as the V3 loop, CD4-induced 
(CD4i) epitopes, and the CD4 binding site (CD4bs; Sanders 
et al., 2000; Saunders et al., 2005; Laakso et al., 2007; Bontjer 
et al., 2009). Of note, the recent discovery of highly potent 
neutralizing antibodies that recognize quaternary epitopes en-
compassing the V2 loop have highlighted once more the po-
tential impact of the V1V2-directed immune response (Gorny 
et al., 2005; Walker et al., 2009). Importantly, on a population 
level, the past decades of continuous neutralizing antibody–
driven evolution of the V1V2 during the pandemic have been 
suggested to have led to the acquisition of longer, more gly-
cosylated V1V2 domains that render current HIV isolates 
increasingly neutralization resistant (Bunnik et al., 2010). Under-
standing how the V1V2 domain steers neutralization sensitivity 
is thus of pivotal importance to allow vaccine-induced antibody 
responses to be tailored to counteract its effect.
How V1V2 shielding is provided for in the context of the 
native Env spike necessitates the definition of the three- 
dimensional geometry of the spike and in particular the inter-
subunit contact areas. Although over the years crystal structure 
analysis of the HIV Env has unraveled structural features of 
ligand-bound and unliganded, monomeric gp120 variants at 
great depth and at high resolution (Kwong et al., 1998, 2000, 
2002; Chen et al., 2005; Zhou et al., 2007; Chen et al., 2009; 
Diskin et al., 2010; Finzi et al., 2010; Kong et al., 2010; Pancera 
et al., 2010; Xiang et al., 2010), structural information on the 
variable loops within HIV-1 gp120 is still scarce (Huang et al., 
2005) and in the case of the V1V2 loop missing. Earlier stud-
ies have proposed a potential intersubunit contact between 
Figure 1. Effect of V1V2 shielding on plasma antibody 
neutralization. (A) Cross-neutralization activity (50%) was  
investigated in 83 plasma samples from individuals chronically 
infected with divergent HIV subtypes (indicated by differentially 
colored data points). Neutralization activity against six WT  
viruses (left) and corresponding V1V2-deleted mutants (right) 
are shown. (B) Efficacy of patient plasma antibody binding to  
WT or V1V2-deleted gp120 (50%) was estimated by ELISA.  
(A and B) Data are derived from two to three independent experi-
ments. The dashed lines correspond to the lowest plasma dilution 
tested (1:100). Fold increases (x) in median neutralization and 
binding titers of V1V2-deleted Env’s compared with the corre-
sponding WT Env are indicated above each panel.
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may quantitatively represent only a small fraction of the over-
all binding antibodies in patient sera.
Delineating neutralizing antibody epitopes shielded  
by the V1V2 domain
To understand which neutralizing antibody epitopes are pro-
tected by the V1V2, we probed the shielding effect of the 
V1V2 domain for mAbs targeting diverse epitopes within 
gp120 and gp41 by comparing their ability to neutralize WT 
and V1V2-deleted viruses or to bind to respective mono-
meric gp120 proteins (Fig. 2 and Tables S1 and S2). Of all the 
epitope specificities probed, V1V2 shielding had the most dra-
matic effect on V3 loop antibodies with up to 240,000-fold 
higher neutralization titers against a V1V2-deleted virus. 
Masking by the V1V2 of both V3 loop and CD4bs was depen-
dent on the trimeric state of the Env, as binding efficacies to WT 
and mutant gp120 proteins were essentially identical (Fig. 2). 
gp41-specific reagents were included as controls as direct 
V1V2 shielding of these epitopes is unlikely. Accordingly, 
only modest effects on their inhibitory capacity were evident, 
confirming that V1V2 deletion did not inflict gross changes 
in entry efficacy or trimer stability that 
would impair further analysis using 
these mutants. Neutralization potency 
of CD4i-specific mAbs increased in 
comparison only moderately, and no 
or only modest effects were evident 
for the glycan-specific mAb 2G12. 
Interestingly, CD4bs-directed inhibi-
tors were differentially affected by V1V2 
shielding. Depending on the isolate 
probed, CD4bs mAbs b12 and VRC01 
either neutralized with identical or 
decreased activity in the absence of 
the V1V2, highlighting that these 
antibodies have found a unique way 
to bypass or even take advantage of the 
V1V2 domain. All other CD4bs agents 
probed (tetrameric CD4-IgG2, mAbs 
Of note, the neutralization-sensitive, CXCR4-using, T cell 
line–adapted virus NL4-3 portrayed the least increase (6.9-
fold) in susceptibility to neutralization upon removal of its 
V1V2 domain. Although absolute neutralization titers against 
V1V2-deleted SF162 matched those of the other four R5 vi-
ruses, the fold increase in neutralization sensitivity of SF162 
upon V1V2 deletion was also lower (40-fold) as SF162 WT 
was efficiently inhibited by the patient plasma samples. Plasma 
neutralization titers against the V1V2-deleted isolates were 
tightly correlated (Table S5), suggesting that common anti-
body types were elicited across subtypes that target conserved, 
highly neutralization-sensitive epitopes usually shielded by 
the V1V2 domain. Interestingly, although gp120 binding and 
neutralization efficacies correlated (Table S5), only modest 
increases in binding efficacy of V1V2-deleted gp120 were 
evident (Fig. 1 B and Table S4). The latter strongly supports 
the notion that the V1V2 domain exerts its full shielding 
effect only in the context of the intact viral spike and not 
on monomeric gp120. Nevertheless, a comparison of binding 
and neutralizing antibodies in the context of polyclonal plasma 
has to be interpreted with caution as neutralizing antibodies 
Figure 2. The V1V2 shapes inhibitory 
activity of neutralizing antibodies. The 
50% inhibitory (left) and 50% gp120 binding 
concentrations (right) of HIV Env–specific 
antibodies and inhibitors (listed on the x axis) 
against WT and the corresponding V1V2-
deleted Env viruses (SF162, NL4-3, JR-FL*, 
REJO, RHPA, and c10.14) are shown. The 
dashed lines represent the highest concentra-
tion tested (50 µg/ml and 25 µg/ml for neu-
tralization and binding assays, respectively). 
Targets of antibodies and inhibitors are shown 
on the right. Data are derived from two to 
three independent experiments. PNGS, poten-
tial N-linked glycosylation site.
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The V1V2 loop counteracts a potent R5 V3 loop–specific 
cross-neutralization activity commonly elicited in vivo
Our data highlight a remarkably potent effect of the V1V2 
shielding on V3 loop–specific mAbs that was comparable in 
magnitude with the increase in neutralization of V1V2-deleted 
viruses by patient plasma (Fig. 1 A). It was thus prudent to 
probe whether V3 loop–specific antibodies are the dominant 
category of cross-neutralizing antibodies elicited in HIV in-
fection that are counteracted by the V1V2 loop. To this end, 
we compared the neutralization activity of subtype B plasma 
samples against V1V2-deleted viruses in the presence or 
absence of competing peptide encompassing the tip of their 
cognate V3 loop (Fig. 3, A and B; and Table S1). The out-
come of these experiments was astonishingly clear. Cross-
neutralization activity against the V1V2-deleted R5 viruses 
SF162, JR-FL*, and 10.14 diminished by several orders 
of magnitude in the presence of the competing V3 loop 
peptide in the majority of the probed plasma samples. Thus, 
V3 loop–reactive antibodies are commonly elicited in HIV in-
fection and are counteracted by the V1V2 domain. Of note, 
a >90% proportion of the plasma neutralization activity was 
caused by V3 loop–directed antibodies in 26, 24, and 14 of the 
28 probed plasma samples for SF162, JR-FL*, and 10.14, 
respectively (Fig. 3 C). In sharp contrast to the R5 isolates, 
the NL4-3 V3 loop peptide in large failed to outcompete 
NL4-3–directed cross-neutralizing plasma activity. Neutral-
ization of NL4-3V1V2 virus in the absence of V3 loop 
b6 and 1F7) greatly improved neutralization activity upon 
V1V2 deletion for those isolates that were not inhibited as 
efficiently as WT, indicating a substantial influence of the 
V1V2 domain on access to their respective epitopes. In sum, 
our data suggest that the ability of b12 and VRC01 to bypass 
or take advantage of the V1V2 in binding to the trimeric 
spike likely accounts for their broad and potent activity. We 
next compared binding of mAbs to monomeric WT and 
V1V2-deleted gp120 proteins to obtain initial insight whether 
the V1V2 masking of their respective epitopes occurs in the 
context of the trimer or monomer (Fig. 2). Notably, only 
CD4i mAbs improved their binding capacity to the V1V2-
deleted gp120 proteins, suggesting that in the absence of 
CD4 triggering, access to CD4i epitopes on monomeric 
gp120 is restricted by the V1V2 loop. Alternatively, the in-
trinsic equilibrium between gp120 conformations that do not 
present the CD4i domain versus such that do may favorably 
be shifted toward the latter in the absence of the V1V2 loop.
Accessibility to all other probed epitopes on monomeric 
gp120 was not influenced by the V1V2 loop, and binding of 
mAbs to WT and V1V2-deleted monomeric gp120 occurred 
at comparable levels. Of particular note, this was also true for 
inhibitors targeting the CD4bs and the V3 loop, which were 
neutralized with a several magnitude higher potency in the 
absence of the V1V2 loop. Thus, effective shielding of these 
domains by the V1V2 loop entirely depends on the organiza-
tion of the Env proteins in the native, trimeric spike.
Figure 3. Linear V3 loop peptides compete off V1V2-shielded plasma neutralization activity. Quantification of the contribution of V3 loop anti-
bodies to plasma neutralization by the addition of V3 loop peptides to compete off V3 loop–reactive antibodies. (A) Inhibition profiles of JR-FL* by plasma 
from two individuals with chronic subtype B infection in the presence (red) or absence (black) of a peptide spanning the tip of the JR-FL V3 loop (Table S1). 
Representative inhibition profiles from two independent experiments for an individual with a high (patient 109) and an individual with no (patient 125) 
measurable V3 loop–directed activity in plasma are shown. The dotted line denotes 0% neutralization, and the dashed line denotes 50% neutralization. 
(B) Analysis of V3 loop antibody contribution to V1V2-deleted virus neutralization in 28 plasma samples derived from chronic subtype B infection. 50% 
neutralization titers in the presence (red) or absence (black) of the corresponding V3 loop peptide are shown. (C) The fraction of V3 loop–reactive neutral-
izing antibodies in patient plasma as determined in B is depicted. The dotted line denotes 0% neutralization, and horizontal bars denote medians.  
(D) Quantification of neutralizing antibodies in patient plasma from individuals infected with non-B subtypes that cross-react with the V3 loop of JR-FL. 
(B and D) Dashed lines indicate lowest plasma dilution probed (1:100). (B–D) Data are derived from two to three independent experiments. For details on 
statistical analysis, see Materials and methods.
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neighboring protection; Fig. 4). Self protection by the V1V2 
loops would thereby depend on a substantially altered con-
formation of the gp120 subunit in the context of the mono-
mer as opposed to the trimer, as only the latter is protected 
from neutralization by the V1V2 loop (Figs. 1, 2, and 4).
In this study, we devised a mathematical model and an 
experimental strategy that allows us to distinguish between 
neighboring and self protection modes of the V1V2 domain. 
Our chief interest was to define how the V1V2 creates pro-
tection for the V3 loop. The basic principle of our approach 
is to probe the V1V2 shielding effect on the V3 loop in the 
context of heterogenous Env trimers that are composed of 
two different types of Env proteins (Fig. 5 A). One WT Env 
protein (sensitive, harboring V1V2) contains the epitope of 
the neutralizing V3 loop antibodies 19b and 1-79. The other 
Env does not contain the epitope for these V3 loop mAbs 
and was in addition V1V2 deleted (resistant, V1V2). By 
cotransfecting altering ratios of the two Env-expressing plas-
mids, cell populations with varying compositions of Env tri-
mers can be generated that consequently differ in the fraction 
of Env proteins sensitive to V3 loop mAb binding. Depending 
on whether self or neighboring protection occurs, distinct 
binding scenarios will be observed (Fig. 5 A).
To differentiate between the two alternative protection 
scenarios, we devised a mathematical model that predicts the 
mean number of antibodies bound to a trimer as a function of 
the fraction of Env proteins carrying the V3 loop mAb–sensitive 
epitope (Fig. 5 B). Because of the random nature of trimer 
formation, spikes that contain zero, one, two, or three mAb-
sensitive epitopes will form. However, binding of mAb to 
sensitive V3 loops will only occur on heterotrimers where 
V1V2 shielding is not effective and will thus depend on whether 
V1V2 mediates neighboring or self protection (Fig. 5 A). 
Accordingly, our mathematical model predicts distinct V3 loop 
mAb–binding patterns in cell populations expressing different 
compositions of heterotrimers (Fig. 5 B). If the V1V2 loop 
masks the V3 loop mAb–binding site of the Env protein it 
originates from, no mAb binding should be observed (Fig. 5 B, 
green line). In contrast, if the V1V2 loop masks an antibody-
binding site of a neighboring Env protein, 
binding to several trimer configurations 
can occur (Fig. 5 A), and our model predicts 
a hump-shaped curve (Fig. 5 B, blue line). 
Thus, using our mathematical model, we 
predicted distinct, unmistakably discernable 
competition was significantly lower compared with all other 
probed V1V2 viruses (one-way analysis of variance post-
test, Tukey’s multiple comparison). However, the fraction of 
non-V3 loop–reactive antibodies against NL4-3 was compa-
rable with those of the other probed viruses (no significant 
difference, same test), underlining the fact that V3 loop anti-
bodies do not (or only marginally) contribute to NL4-3 
cross-neutralization activity commonly elicited in vivo. The 
latter likely also accounts for the comparatively low plasma 
cross-neutralization activity against V1V2-deleted NL4-3 
(Fig. 1 A). Whether this reflects a lack of cross-reactivity with 
specifically the V3 loop of NL4-3 or whether X4 V3 loop–
reactive antibodies are generally less frequently elicited in vivo 
needs to be determined. Humoral immune responses that cross-
react with subtype B/R5 V3 loops are commonly elicited in 
infections of other subtype as JR-FL V3 loop–specific pep-
tide potently competed off JR-FL* cross-neutralizing anti-
bodies in subtypes A, C, AE, and AG plasma (Fig. 3 D). Of 
note, we found that plasma neutralization activity against 
WT SF162 is in part mediated by V3 loop–specific antibodies 
(Fig. S1, B and C). Yet, loss of V1V2 shielding increases 
V3 loop mAb sensitivity of SF162 substantially (Fig. 3), indi-
cating that V1V2 shielding is, albeit at a lower level, also 
effective in the context of tier 1 isolates.
The V1V2 loop shields neutralization-sensitive domains  
on neighboring gp120 units
Unraveling the molecular basis of the shielding effect con-
ferred by the V1V2 loop in the context of the Env spike 
would provide much needed knowledge on the loop inter-
action within trimers and overall quaternary trimer architecture 
not yet available from crystal structure and cryoelectron 
microscopy analysis. In principle, two mechanisms can be 
envisaged and have been suggested (Kwong et al., 2000; Chen 
et al., 2005; Zhu et al., 2006; Liu et al., 2008a; White et al., 
2010; Wu et al., 2010): the V1V2 domain can either protect 
domains in the gp120 subunit it originates from (intrasubunit, 
self protection) or alternatively act by shielding domains in an 
adjacent gp120 unit within the trimeric spike (intersubunit, 
Figure 4. Self and neighboring protection 
scenarios of the V1V2 loop. The V1V2 loop can 
theoretically shield the V3 loop by neighboring 
protection (model 1), in which the V3 loop of a 
neighboring gp120 subunit is protected, or by self 
protection (model 2), in which the V3 loop of the 
own subunit is protected. Circles denote gp120 
monomers. Blue rectangles denote the V3 loop. 
Gray shaded areas depict the V1V2 loop.
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to associate into trimers, we repeated these experiments with 
two alternate Env pairings that only differed in their V3 loop 
sequence and the presence and absence of the V1V2 loop 
(Fig. 5, D and E). In both instances, we again observed a 
hump-shaped reactivity pattern for mAbs 19b (Fig. 5, D and E) 
and 1-79 (Fig. 5 E), supporting the notion that both genetically 
divergent and closely related Env subunits form heterotrimers.
We further verified the V1V2 protection modus by as-
sessing an alternate trimer scenario (setup 2) in which the 19b 
epitope is exposed on the V1V2-deleted Env protein, whereas 
the WT Env is resistant to 19b (Fig. 6, A–C). In this scenario, 
our model predicts reactivity patterns that are less divergent 
as binding in both settings is possible. If the self protection 
scenario holds true, our model predicts a straight line, and if 
binding reactivity patterns for the self and neighboring pro-
tection scenarios.
We next probed our model experimentally and assessed 
mAb 19b binding to 11 different cell populations expressing 
varying compositions of heterotrimers composed of Env’s 
NL4-3V1V2 (lacking the V3 loop mAb epitope) and JR-FL* 
(harboring the V3 loop mAb epitope; Fig. 5 C). The data 
provided a strikingly clear pattern: 19b binding followed a 
hump-shaped curve, suggesting that neighboring protection 
is the mode by which the V1V2 domain shields the V3 loop. 
The same pattern of reactivity was observed for a second 
V3 loop mAb, 1-79. Of note, our approach relies on a random 
formation of heterotrimers. As the experiment depicted in 
Fig. 5 C necessitates two genetically divergent Env proteins 
Figure 5. Dissection of self and neighboring protection scenarios of the V1V2 loop using mathematical modeling and empirical binding  
experiments to Env trimers. V1V2 loop shielding of the V3 loop was studied by binding of the V3 loop–specific mAbs 19b and 1-79 to heterogenous 
Env trimers that differ in V3 loop epitope presentation. Heterotrimer-expressing cells are generated by cotransfection of two different Env genes: a WT Env 
that is sensitive to the V3 loop mAbs and a V1V2-deleted Env (V1V2) that carries a resistant V3 loop. (A) The schematic indicates the theoretical number 
of V3 loop mAb–accessible epitopes for all potential heterotrimer conformations assuming either self (green shaded area) or neighboring protection (blue 
shaded area) for the two respective Env’s. Blue squares denote V3 loops sensitive to mAbs 19b and 1-79, and red squares denote resistant Env’s. Gray 
shaded areas indicate V1V2 loops. (B) Predicted binding curves (MFI) for V3 loop mAbs under the binding scenarios depicted in A using our mathematical 
model. Green denotes self and blue denotes neighboring protection. Ratios of resistant to WT Env proteins are indicated on the x axis. (C–E) Experimental 
binding data. mAb 19b (circles) and 1-79 (triangles) binding to cells expressing the indicated heterotrimers at varying ratios was studied by FACS. Data of 
two to three independent experiments are shown. The highest MFI measured in each experiment was set as the maximum fluorescence level (100%), and 
measured MFI signals were normalized to the percentage of maximum fluorescence (% max). Dotted lines correspond to the minimum and maximum 
fluorescence levels (O adn 100%). Unprocessed MFI data for mAbs 19b and 2G12 (to monitor total Env expression) are depicted in Fig. S2.
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neighboring and self protection can be dissected as described 
in setups 1 and 2 (Fig. 7).
To exclude the possibility that nonequal Env expression 
confounds our findings, gp120 expression levels on the vari-
ous cell populations were monitored in all shielding experi-
ments by assessing reactivities of the V3 loop mAb 19b and 
the carbohydrate-specific mAb 2G12 to control for V3 epi-
tope and total gp120 Env expression, respectively (Fig. S2). 
Although Env expression varied to some extent between 
experiments and depended on the Env pairs studied, suffi-
cient expression allowing assessment of mAb binding by 
FACS was achieved throughout. Fluctuations in Env expres-
sion levels are however unavoidable (Fig. S2; comparison of 
2G12 binding to 100% sensitive and 100% resistant Env). As 
the observed differences were relatively small, we chose not to 
normalize the data by correcting for Env expression, as actual 
differences in Env expression and influences of differential mAb 
affinity for the heterologous Env pairs are difficult to tease 
apart. Importantly, variation in total Env expression levels was 
in all instances associated with a slight overexpression of one 
of the Env’s, never with a decrease for cell populations that 
contain higher fractions of heterotrimers. From this, we con-
clude that the generated heterotrimers were stable and not 
genuinely prone to spontaneous gp120 shedding. The latter 
was important to verify as V1V2 shielding would not be ef-
fective on partially shed trimers and would report false posi-
tive signals in our system. We found that JR-FL*WT was 
expressed at slightly higher levels than NL4-3V1V2 in most 
experiments, which corresponded with a modest rightward skew 
of the hump-shaped binding curves (Fig. 5 C). In an alternate 
the neighboring protection holds true, we predict a convex 
curve. Experimental probing retrieved a convex-shaped reactiv-
ity pattern, again suggesting neighboring protection (Fig. 6 C).
Although our data carved out neighboring protection as 
the mode by which the V1V2 domain protects the V3 loop, 
we sought to further ascertain that our experimental approach 
is valid and is indeed capable of distinguishing between neigh-
boring and self protection. Our approach depends on two 
key parameters: for one that heterotrimers form and, second, 
that heterotrimers consisting of WT and V1V2-deleted sub-
units adopt a conformation that resembles the WT-enabling 
V1V2 shielding to occur. Should the trimer assemble in a 
more open formation when WT and V1V2-deleted Env’s are 
mixed, V1V2 shielding could be lost, allowing mAbs to ac-
cess the V3 loop. To verify that heterotrimers form and have 
the appropriate conformation, we performed a control ex-
periment (Fig. 7). Here, two identical Env’s with a sensitive 
V3 loop that only differed in the presence/absence of the V1V2 
loop were paired. When heterotrimers adopt the appropriate 
conformation and V1V2 shielding is intact, then irrespective 
of whether neighboring or self protection occurs, a linear in-
crease in V3 loop mAb–accessible sites should be observed in 
this setup (Fig. 7, blue and green straight lines). In contrast, if 
heterotrimers assemble in a formation that jeopardizes V1V2 
shielding, the V3 loop would be accessible in all heterotri-
mers, and the reactivity pattern in this case would dramati-
cally shift to the left (Fig. 7 B, gray curve). Experimental 
probing revealed a straight line reactivity pattern, confirming 
that heterotrimers with intact shielding must form. These re-
sults verify that our model assumptions are correct and that 
Figure 6. Dissection of self and neighboring protection in an alternate shielding scenario. V1V2 loop shielding of the V3 loop was studied by binding 
of the V3 loop–specific mAb 19b to heterogenous Env trimers that differ in 19b epitope presentation. Heterotrimer-expressing cells were generated by  
cotransfection of two different Env genes: a WT Env that is resistant to the V3 loop mAb (NL4-3) and a V1V2-deleted Env (V1V2) that carries a 19b-sensitive 
V3 loop (JR-FL* V1V2). (A) The schematic indicates the theoretical number of V3 loop mAb–accessible epitopes for all potential heterotrimer conformations 
assuming either self (green shaded area) or neighboring protection (blue shaded area) for the two respective Env’s. Blue squares denote V3 loop sensitive to 
mAb 19b, and red squares denote resistant Env’s. Gray shaded areas indicate V1V2 loops. (B) Predicted binding curves for V3 loop mAbs under the binding 
scenarios depicted in A using our mathematical model. Green denotes self and blue denotes neighboring protection. Ratios of resistant to WT Env proteins are 
indicated on the x axis. (C) Experimental binding data. mAb 19b (circles) binding to cells expressing the indicated heterotrimers at varying ratios was studied 
by FACS. Data of three independent experiments are shown. The highest MFI measured in each experiment was set as the maximum fluorescence level 
(100%), and measured MFI signals were normalized to the percentage of maximum fluorescence (% max). Dotted lines correspond to the minimum and maxi-
mum fluorescence levels (O adn 100%). Unprocessed MFI data for mAbs 19b and 2G12 (to monitor total Env expression) are depicted in Fig. S2.
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(Moore et al., 1990; Moore et al., 2006; Ruprecht et al., 2011). 
In the context of monomers or dimers, V3 loops will not be, 
or only imperfectly, shielded (Fig. 2). As V3 loop mAb binding 
to monomers and dimers could influence our readout, we 
modeled the potential influence of partially shed spikes in our 
shielding analysis. We found that the presence of monomers 
and dimers induces a small rightward skew of the hump-
shaped binding pattern (Fig. S3 D), which could add to the 
observed skewing in some of our experiments (Fig. 5 C). 
Monomer and dimer binding could also potentially influence 
the binding pattern in the alternate shielding scenarios (Figs. 6 
and 7), although to an even smaller extent (Fig. S3, E and F).
In summary, we conclude that our experimental approach 
to uncover the mechanistic basis of V1V2 loop shielding is 
very robust. Small deviations from the in silico–derived re-
activity patterns can occur when shielding is probed in vitro. 
However, these differences are marginal and are accounted 
for by differences in Env expression levels and the presence 
of monomeric and dimeric gp120 on the transfected cells.
DISCUSSION
Advances in recent years have highlighted the significant 
impact of the V1V2 domain on steering the sensitivity to 
antibody neutralization (Cao et al., 1997; Chackerian et al., 
1997; Fox et al., 1997; Morikita et al., 1997; Stamatatos and 
Cheng-Mayer, 1998; Ly and Stamatatos, 2000; Losman et al., 
2001; Johnson et al., 2003; Cole et al., 2004; Pinter et al., 
2004; Pugach et al., 2004; Krachmarov et al., 2005, 2006; 
Saunders et al., 2005; Sagar et al., 2006; Shibata et al., 2007; 
Ching et al., 2008). Collectively, these studies point toward 
pairing, JR-FL*V1V2V3NL4-3 was expressed at higher levels 
than JR-FL*WT, which is consistent with a modest leftward 
skew of the binding pattern observed in Fig. 5 E. Thus, non-
equal expression levels may in part cause slight, off-center 
skewing of the hump-shaped reaction patterns.
In a series of additional modeling approaches, we verified 
the influence of further parameters on our shielding assay to 
rule out the possibility that other confounding factors exist 
that affect our analysis and conclusions. In a first approach, 
we probed whether nonrandom trimer formation (i.e., pref-
erential homotrimer formation) could affect our experimental 
approach. However, mathematical modeling of the potential 
influence of homotrimers on the hump-shaped reactivity pat-
tern confirmed that, regardless of the frequency by which 
homotrimers are generated, no shift in the reactivity pattern 
can occur as mAb binding in this scenario completely depends 
on heterotrimer formation (Fig. S3 A). In this sense, our ex-
perimental approach provides also a formal proof that hetero-
trimer formation occurs.
Although we found that skewing of the hump-shaped re-
action pattern cannot be explained by preferential homotri-
mer formation, this could affect the alternate shielding scenario 
(setup 2) to some extent and needs to be factored in when 
solely this protection scenario is used for assessments (Fig. 6 
and Fig. S3 B). Of note, the influence of homotrimer forma-
tion cannot be assessed in the protection scenario studied in 
setup 3 (Fig. 7 and Fig. S3 C).
Besides intact trimers, partially shed spikes composed 
of gp120 dimers or monomers or solely gp41 stumps are 
expressed on infected or Env-transfected cells and virions 
Figure 7. V1V2 loop shielding is intact in heterotrimers consisting of WT and V1V2-deleted subunits. (A–C) The capacity of the V1V2 loop to shield 
the V3 loop was assessed by studying binding of the V3 loop–specific mAbs 19b and 1-79 to chimeric Env trimers expressed on transfected 293-T cells. Env 
subunits used to generate the heterotrimers differed only in the presence/absence of the V1V2 loop. (A) Schematics indicating the theoretical number of 19b- 
and 1-79–accessible epitopes for all potential heterotrimer conformations assuming either self (green shaded area) or neighboring protection (blue shaded 
area) for the two indicated Env pairs. Blue squares denote V3 loop sensitive to mAbs 19b and 1-79. Gray shaded areas indicate V1V2 loops. (B) Predicted bind-
ing curves for V3 loop mAbs under the binding scenario depicted in A using our mathematical model. Green denotes self and blue denotes neighboring pro-
tection when heterotrimers are intact and confer V1V2 shielding. The gray line indicates the predicted binding pattern if heterotrimers have lost the capacity 
for V1V2 shielding. By varying expression ratios of the two respective Env proteins (indicated on the x axis), cell populations with higher or lower degree of 
heterotrimer conformations can be formed and are used in our model to predict binding patterns. (C) Experimental binding data. 19b (circles) and 1-79 (tri-
angles) binding to 293-T cells expressing the indicated heterotrimers at varying ratios (indicated on the x axis) was studied by flow cytometry. Data of three 
independent experiments are shown. The highest MFI measured in each experiment was set as the maximum fluorescence level (100%), and measured MFI 
signals were normalized to the percentage of maximum fluorescence (% max). Dotted lines correspond to the minimum and maximum fluorescence levels  
(O adn 100%). Unprocessed MFI data for mAbs 19b, 1-79, and 2G12 (to monitor total Env expression) are depicted in Fig. S2.
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rearrangements upon sequence variation must be carefully 
evaluated in this type of analysis. The latter holds particularly 
true when the contribution of glycosylation is evaluated as 
removal of the specific potential N-linked glycosylation site 
necessitates changes in the amino acid backbone, which by 
themselves may cause structural rearrangements. In our cur-
rent study, we explored the V1V2 shielding modus in the 
context of a neutralization-sensitive, tier 1 Env, NL4-3, and 
a relatively neutralization-resistant, tier 2 Env, JR-FL. 
Although V1V2 domains of these Env’s differ in their degree 
of glycosylation, both were capable of protecting the adjacent 
gp120 molecule’s V3 loop in the context of the trimer. The 
latter supports the notion that the V1V2 domain has an in-
trinsic capacity to confer protection throughout all disease 
stages and is, albeit at a lower level, also active in the setting 
of tier 1 viruses (Fig. S2).
Although our study does not provide data on the physical 
structure of the V1V2 domain per se, it offers new informa-
tion on the quaternary organization of the V1V2 loop in the 
context of the Env trimer. The results of our analysis fit well 
with currently available structural data of gp120 and proposed 
models of the quaternary geometry of gp120 subunits within 
the trimeric spike (Kwong et al., 1998, 2000; Chen et al., 
2005; Huang et al., 2005; Zanetti et al., 2006; Zhu et al., 
2006; Liu et al., 2008a; Chen et al., 2009; Diskin et al., 2010; 
Finzi et al., 2010; Kong et al., 2010; Pancera et al., 2010; 
White et al., 2010; Xiang et al., 2010; Hu et al., 2011). 
A potential interaction of the V1V2 domain with the adjacent 
monomer’s V3 loop has been considered for long (Kwong 
et al., 2000; Chen et al., 2005) but until to date could not be 
confirmed in the absence of the definition of a high-resolution 
trimer structure. Of note, results from recent cryo-ET studies 
of HIV Env spikes appear compatible with an interaction of 
V1V2 and V3 loops of neighboring subunits on the tip of the 
spike, but these analyses yet lack in resolution to unambigu-
ously confirm such an interaction (Liu et al., 2008a; White 
et al., 2010; Hu et al., 2011). Our study confirms the prox-
imity of the V1V2 and V3 loops of neighboring gp120 sub-
units within the trimeric spike and thus aids in validating the 
current models of Env trimer structure. By formally defining 
the orientation of the V1V2 loop toward the neighboring 
subunit in the trimer, our data close an important gap in the 
understanding of the structural architecture of the trimeric 
spike and provide a molecular basis on how the V1V2 masks 
neutralization-sensitive domains.
MATERIALS AND METHODS
Reagents and clinical specimen. Antibodies used in this study were 
made available by J. Robinson (Tulane University Medical Center, New 
Orleans, LA), M. Nussenzweig (The Rockefeller University, New York, 
NY), D. Burton (The Scripps Research Institute, La Jolla, CA), H. Katinger 
(Polymun Scientific, Vienna, Austria), S. Zolla-Pazner (New York Univer-
sity School of Medicine, New York, NY), J. Mascola (Vaccine Research Cen-
ter, National Institutes of Health, Bethesda, MD), and the AIDS Research and 
Reference Reagent Program (Division of AIDS, National Institute of Al-
lergy and Infectious Diseases, National Institutes of Health). The precise origin 
and epitope specificities of mAbs used in this study are listed in Table S2. 
very effective epitope masking by the V1V2 loop. The obser-
vation that currently circulating HIV strains have evolved 
their V1V2 domain to gain in neutralization resistance (Bunnik 
et al., 2010) supports the notion that the V1V2 loop provides 
an essential barrier for neutralizing antibodies elicited in nat-
ural infection. We reasoned that the protective effect of the 
V1V2 must be dominant to allow for such a focused evolu-
tion. Indeed, as we show in this study, the V1V2 domain has 
a tremendous capacity to protect against the humoral im-
mune response elicited in vivo. The effect was particularly 
pronounced for more neutralization-resistant, primary tier 
2 and 3 isolates, whereas neutralization-sensitive strains, as used 
in previous assessments of the V1V2 shielding effect (Morikita 
et al., 1997; Ly and Stamatatos, 2000; Losman et al., 2001; 
Pinter et al., 2004; Pugach et al., 2004; Krachmarov et al., 
2005, 2006; Ching et al., 2008; Bontjer et al., 2009), under-
appreciated its magnitude. Unmasking of V1V2-protected 
domains unraveled a potent neutralization activity ubiqui-
tously elicited in chronic infection across genetic subtypes. Most 
intriguingly, we found that this neutralizing activity was to a 
large extent conferred by V3 loop–specific antibodies, which 
cross-reacted with genetically divergent R5 V3 loop domains 
but not an X4 V3 loop. As the investigated chronic infection 
cohort did not include late stage infection, the lack of X4 
cross-reactivity may reflect the predominance of R5 strain 
infections at the explored disease stage. mAb studies supported 
the tremendous impact of the V1V2 on shielding the V3 loop 
(Ly and Stamatatos, 2000; Losman et al., 2001; Krachmarov 
et al., 2005, 2006). However, our results also highlight shield-
ing effects of the V1V2 on other neutralization-sensitive do-
mains, further supporting its role as a broadly active barrier 
for neutralization in the context of the native trimer.
To date, the molecular basis of the V1V2 shielding capac-
ity remains uncertain, largely as high-resolution structural in-
formation of the loop orientation in the context of intact HIV 
trimers is not available. Recent cryo-ET studies suggest that 
V1V2 and V3 loops may interact in the apex of trimeric Env 
spikes (White et al., 2010; Hu et al., 2011). In this study, we 
report on a structure–function analysis based on a specifically 
devised mathematical model and an experimental strategy to 
probe the theoretical assumptions. By studying V3 loop acces-
sibility in the context of heterogeneous Env trimers composed 
of gp120 units with or without the V1V2 domain, we were 
able to demonstrate that the V1V2 loop protects the V3 loop of 
a neighboring gp120 in the context of the native trimer. Thus, 
the HIV-1 Env trimer adopts a quaternary structure that effec-
tively shields highly cross-neutralization–sensitive domains by 
enforcing intersubunit contact through the V1V2 domain.
Further analysis will be needed to define whether and 
how increases in length and glycosylation within the V1V2 
steer the efficacy of the intersubunit interaction and thus po-
tentially improve shielding. However, a meaningful dissec-
tion of the contribution of sequence changes, glycosylation 
patterns, and length variation on V1V2 functionality will de-
pend on the availability of crystal structure data of the V1V2 
domain, as naturally occurring and artificially induced structural 
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Virus preparation. Env-pseudotyped viruses were prepared by cotransfec-
tion of 293-T cells with the plasmids encoding the respective Env genes and 
the luciferase reporter HIV vector pNLluc-AM as described previously 
(Rusert et al., 2009).
Neutralization assay using Env-pseudotyped virus. The neutralization 
activity of mAbs and patient plasma was evaluated on TZM-bl cells as de-
scribed previously (Rusert et al., 2009). Virus input was chosen to yield virus 
infectivity corresponding to 5,000–20,000 RLU (relative light units) in the 
absence of inhibitors. The antibody concentrations or reciprocal plasma titers 
causing 50% reduction in viral infectivity (inhibitory concentration IC50 or 
neutralization titer NT50) were calculated by fitting pooled data from two to 
three independent experiments to sigmoid dose–response curves (variable 
slope) using Prism software (GraphPad Software). If 50% inhibition was not 
achieved at the highest or lowest drug or plasma concentration, a greater 
than or less than value was recorded.
Neutralization assay in the presence of competing linear V3 loop 
peptides. Neutralization assays were performed in the presence of linear pep-
tides compromising the aa 301–324 (HxB2) of the corresponding V3 loop: 
JR-FL–V3, NNTRKSIHIGPGRAFYTTGEIIG; NL4-3–V3, NNTRK-
SIRIQRGPGRAFVTIGKIG; SF162-V3, NNTRKSITIGPGRAFYATG-
DIIG; and c10.14-V3, NNTRRSIHIGPGKAFYTGGIIG. We used a fixed 
concentration of 10 µg/ml of the V3 peptides in all experiments. This dose of 
V3 peptide was sufficient to completely compete off neutralization activity of 
the V3 loop–specific mAb 19b against JR-FL*V1V2 at mAb concentrations 
of 50 µg/ml. None of the probed peptides directly influenced the infectivity 
of the probed R5 and X4 viruses, and murine leukemia virus Env–pseudotyped 
virus was used as control. Patient plasma samples were preincubated with the 
corresponding V3 loop peptides for 1 h. Then virus was added, and the mix-
ture was preincubated for a further 1 h before infection of TZM-bl cells. The 
final, lowest dilution of the plasma sample probed was 1:200. 50% inhibitory 
concentration and neutralization activity in the presence and absence of com-
peting V3 loop peptide were determined.
Antibody binding to monomeric gp120. Sequences encoding gp120 WT 
and gp120V1V2 proteins were derived from full-length Env genes and 
cloned into the expression vector CMV-R (provided by P. Kwong [Vaccine 
Research Center, National Institutes of Health]). Protein was generated upon 
transfection of FreeStyle 293 cells (Invitrogen). In brief, 1–106/ml cells in a 
total volume of 100 ml of 293 FreeStyle medium (Invitrogen) were transfected 
with 160 µg DNA and 320 µg polyethyleneimine. gp120-containing super-
natant was harvested on days 3 and 5 and used for binding experiments by 
ELISA. To this end, gp120 proteins were immobilized on ELISA plates coated 
with sheep antibody D7324 directed to the C5 domain of gp120 (Aalto). 
Plasma IgG titers and mAb to gp120 were determined by ELISA as described 
previously (Trkola et al., 2004). Midpoint titers were defined by fitting dose-
dependent curves with a variable slope by Prism software. Each individual 
sample was controlled for unspecific binding activity (binding in absence of 
gp120), and data was corrected for unspecific binding before 50% binding 
titers or concentrations were derived. Curve fitting was constrained at 0% but 
not at 100% binding because plasma and mAbs show comparable but not equal 
saturation levels. In rare cases, anti-gp120 antibody titers in plasma were too 
low to reach binding saturation. To assess binding efficacy in these cases, maxi-
mal binding was set as the mean level of maximal binding observed in the 83 
plasma samples, and curve fitting was performed using this mean level as 100% 
binding. To calculate the 50% binding titers, curves were fitted through the 
pooled data from two to three independent assays.
Mathematical model to dissect self and neighboring protection 
modes of the V1V2 loop. We developed a mathematical model with the 
aim to dissect experimentally whether neighboring or self protection is the 
mode by which the V1V2 loop protects against neutralization. Our theoreti-
cal and experimental approach is based on studying heterogeneous trimers 
composed of two different Env proteins. These Env proteins must differ in 
Plasma samples were obtained from individuals with chronic HIV-1 infection 
(>6 mo infected) enrolled in (a) the Swiss HIV Cohort Study (Schoeni-
Affolter et al., 2010), (b) the Zurich Primary HIV Infection Study (Rieder et al., 
2010), and (c) the Swiss Spanish Treatment Interruption trial (Trkola et al., 2004). 
All experiments were approved by the ethics committee of the University Hos-
pital Zurich, and written informed consent was obtained from all individuals. 
Detailed patient demographics are listed in Table S3. Peptides were provided by 
J. Robinson and T. Riedel (University of Zurich, Zurich, Switzerland).
Cells. 293-T and TZM-bl cells were obtained from the American Type 
Culture Collection and the National Institutes of Health AIDS repository, 
respectively, and cultured as described previously (Rusert et al., 2009).
HIV Env genes. All HIV Env genes used in this study have been previously 
described (Table S1) with the exception of the Env ZA110.C.10.14, which 
was previously isolated in our laboratory from a rapidly progressing individ-
ual during chronic infection (Table S1).
Generation of V1V2-deleted Env’s. An overview of all mutant Env 
genes generated in the frame of this study is provided in Table S1. For the 
construction of V1V2-deleted viruses, the natural restriction sites DraIII (up-
stream) and StuI (downstream) of the V1V2 were used to substitute the original 
V1V2 domain with a 3-aa linker sequence DAG as described previously 
(Fig. S1 A; Bontjer et al., 2009). Env’s were cloned into the expression 
vector pcDNA 3.1. DraIII and StuI restriction sites in pcDNA 3.1 were 
removed before construction of the V1V2 mutant viruses. The integrity of 
the derived mutant Env’s was verified by sequencing, and functionality was 
ascertained in a pseudotype virus infection assay. All Env mutants proved in-
fection competent in pseudotype infection upon V1V2 deletion/DAG insertion. 
As expected, infectivity upon V1V2 deletion decreased to some extent com-
pared with the corresponding WT isolates. However, for all Env’s described 
here, this reduction was <10-fold, and infectivity was in all cases sufficient 
for inhibitor experiments. The only exception was the Env of JR-FL as this 
protein did not tolerate the substitution by its cognate V1V2 linker sequence. 
However, we were able to restore its infectivity by introducing a D197N 
mutation that generates an additional potential N-glycosylation site down-
stream of the V1V2. We designated this virus as V1V2JR-FL* and con-
structed a corresponding WT JR-FL derivative harboring the D197N mutation 
(designated JR-FL*). This modification proved to have no influence on the 
neutralization sensitivity of the virus as we found that both JR-FL and JR-FL* 
had identical sensitivity to neutralization by mAbs and patient plasma.
To generate V3 loop–swapped NL4-3 and JR-FL* Env’s, an overlap ex-
tension PCR was used. The NL4-3 and JR-FL* Env sequences upstream of 
the V3 loop (NL4-3 primers, 5-GAGACAGCGACGAAGAGCTCCTC-3 
and 5-GGGTCTTGTACAATTAATTTCTACAG-3; JR-FL* primers, 
5-CTCAAGACAGTCAGACTCATCTTGC-3 and 5-GTATTGTTGT-
TGGGTCTTGTACAATTAATTTC-3), the individual V3 loops (NL4-3 
primers, 5-GTACAAGACCCAACAACAATACAAG-3 and 5-GTTACA-
ATGTGCTTGTCTCATATTTCC-3; JR-FL* primers, 5-CTGTAGAA-
ATTAATTGTACAAGACCC-3 and 5-GCTCTACTAATGTTACA-
ATGTGC-3), and the NL4-3 and JR-FL* Env sequences downstream of the 
V3 loop (NL4-3 primers, 5-GCACATTGTAACATTAGTAGAGC-3 
and 5-TTTTGACCACTTGCCACCCATCTTATAGC-3; JR-FL* 
primers, 5-TATGAGACAAGCACATTGTAACATTAGTAGAGC-3 
and 5-ACTTTTTGACCACTTGCCACCC-3) were amplified in separate 
PCR reactions. Subsequently, the NL4-3 and JR-FL* Env upstream fragments 
were mixed with the desired V3 loop fragment and subjected to a first overlap 
extension PCR followed by purification of the fusion products by gel extraction. 
The purified fusion products were subjected to a second overlap extension PCR 
with the Env downstream fragments that correspond to the upstream fragment 
yielding the desired chimeric Env gene. The final fusion products were gel puri-
fied and cloned into pcDNA3.1. The sequence of the derived mutant Env’s was 
verified, and epitope accessibility was probed by FACS. Env JR-FL*V1V2_
V3NL4-3 proved not infectious, whereas NL4-3WT_JR-FLV3 was infectious in 
the context of pseudovirus infection.
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the fraction of antibody-sensitive Env proteins, fbs. These predictions are 
shown in Figs. 5 B, 6 B, and 7 B.
Setup 3 does not allow us to distinguish between neighboring and self 
protection as identical reactivity patterns are predicted for both instances. In-
stead, setup 3 allows us to derive information on whether or not the formed 
heterotrimers adopt an appropriate conformation that enables V1V2 shield-
ing to occur. Should the formed heterotrimers disable V1V2 shielding, the 
V3 loop would become accessible. In this case, MFI reactivity patterns would 
change substantially and follow the function
	 3 3 1 3 3 1 32 2 3´ -( ) + ´ -( )+ ´f f f f fD D D D D. 	
Modeling the influence of segregation (preferential homotrimer 
formation) on the reactivity pattern in the shielding assay. In the 
segregation model, we assume that the formation of homotrimers is more 
likely than that of heterotrimers. To assess the potential impact of Env pro-
tein segregation, we introduced a segregation parameter, 0 ≤  ≤ 1, into our 
basic model.  = 0 corresponds to no segregation, and  = 1 corresponds to 
complete segregation. Table II lists the number of antibodies that bind, on 
average, to a trimer with segregation.
The probabilities to form a trimer with i binding–sensitive Env proteins, 
Pi, appearing in Table II are defined according to the segregation model in 
Magnus and Regoes (2010) as
	 P f f f f fbs bs bs bs bs1 1
2 1
1 2 1 1 1 1
1
= -( ) + -( ) -( ) - -( )( )- - -x x x , 	
	 P f f f f fbs bs bs bs bs2 1 1
1 2
2 1 1 1 1= -( )+ -( ) - -( )( )- - -x x x , 	 and
	 P fbs3 3 2= - x . 	
For setup 3, fbs must be replaced by f to obtain the probabilities Pi. As the 
V3 loop is only accessible on heterotrimers in the shielding scenario studied in 
Fig. 5 (setup 1; hump-shaped curve), homotrimer formation, regardless of its 
extent, is not predicted to influence the normalized MFI. In the alternate 
shielding scenario (setup 2; Fig. 6), the V3 loop can be accessed on hetero-
trimers, and their influence, although small, must be considered (Fig. S3 B).
Modeling the influence of gp120 monomers and dimers on the reactiv-
ity pattern in the shielding assay. Additionally to intact trimeric Env spikes, 
partially shed Env spikes displaying gp120 monomers and dimers will be ex-
pressed on the cell surface of Env-transfected cells. V1V2 shielding on these par-
tially shed spikes will not be effective, and the V3 loop will thus be accessible. 
With what frequency monomers and dimers form is not known. Assay variations 
(e.g., transfection and expression efficiencies) can be envisaged to play a role. 
The fraction of Env monomers and dimers may also differ depending on the Env 
proteins involved. The stability of homo- and heterotrimers may differ, render-
ing one more prone to spontaneous gp120 shedding than the other. The latter 
two regions. The first region concerns the V1V2 loop and the second region 
an antibody epitope (in our case the epitope of the V3 loop–specific anti-
bodies 19b and 1-79), which is presumably masked by the V1V2 loop. We 
engineered Env proteins in which the V1V2 loop is either present or de-
leted, and 19b and 1-79 V3 loop mAb epitopes are present or defective (nat-
urally or engineered). Two experimental setups with two different Env 
proteins out of the total eight possible combinations with these four Env 
variations can be used to distinguish between neighboring and self protec-
tion: (1) one Env protein contains the V1V2 loop and is sensitive to antibody 
binding, whereas the other Env protein is V1V2 deleted and antibody bind-
ing resistant; (2) one Env protein contains the V1V2 loop and is resistant to 
antibody binding, whereas the other Env protein is V1V2 deleted and anti-
body binding sensitive.
The schematic in Fig. 5 A shows how many antibodies could bind to 
the different trimers depending on the mechanism of protection in the ex-
perimental setup 1, and Fig. 6 A shows the number of trimers binding to the 
different trimers in setup 2. As a control experiment, we also studied an ex-
perimental setup (setup 3) in which two homologue antibody binding–sensitive 
Env proteins were mixed that only differed in the presence and absence of 
the V1V2 loop. This setup does not allow us to distinguish between neigh-
boring and self protection but instead allows us to validate the integrity of 
heterotrimer formation. Fig. 7 A illustrates how many antibodies can bind to 
the different trimer types that can form in this setup.
In our experiments, we seek to determine the accessibility of the 
V3 loop on trimers by determining the binding efficacy of the given V3 loop 
mAbs by deriving the mean fluorescent intensity (MFI) of fluorophore-labeled 
mAb binding by FACS. The MFI is proportional to the number of antibodies 
binding to the Env-expressing cells. To predict the MFI, we need to 
average the number of bound antibodies over all trimer types in a cell popula-
tion. This requires us to factor in the frequency of each trimer type, which 
depends on the fraction of different Env proteins. Let us define fbs as the 
fraction of Env proteins with a binding-sensitive epitope (independent of 
whether it is protected by a V1V2 loop). Under the assumption that the dif-
ferent Env proteins trimerize perfectly randomly, the probability that a tri-
mer consists of i Env proteins with an antibody binding–sensitive epitope 
and 3  i antibody-resistant Env proteins is
	
i bs
i
bs
i
f f3
3
1( ) -( ) - . 	
For setup 3, all Env proteins are binding sensitive. For this setup, we in-
troduce the parameter f that denotes the fraction of Env proteins without 
V1V2. The frequencies of each trimer type are given by the same formula as 
above with f instead of fbs.
The number of antibodies binding to an average trimer can be calcu-
lated by summing over the products of the number of antibodies binding to 
a specific trimer (determined in Figs. 5 A, 6 A, and 7 A) and the probability 
that this trimer is formed. Table I lists the number of antibodies binding to 
an average trimer for each experimental setup and mode of protection.
To be able to compare our mathematical prediction with the observed 
MFI, we normalize the MFI and the expressions in Table I such that its 
maximum over the various levels of fbs is 1. Thus, we obtained mathematical 
expressions that predict the behavior of the normalized MFI as a function of 
Table I. Mathematical models for the number of antibodies bound per trimer
Setup Neighboring protection Self protection
1
1 3 1 1 3 1
2 2´ -( ) + ´ -( )f f f fbs bs bs bs
0
2 1 3 1 32 3´ -( )+ ´f f fbs bs bs 1 3 1 2 3 1 32 2 3´ -( ) + ´ -( )+ ´f f f f fbs bs bs bs bs
3
1 3 1 2 3 1 3
2 2 3´ -( ) + ´ -( )+ ´f f f f fD D D D D 1 3 1 2 3 1 3
2 2 3´ -( ) + ´ -( )+ ´f f f f fD D D D D
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Env-encoding plasmids were transfected. To vary the heterogeneous trimer 
composition, cells were transfected with different ratios of the two respective 
Env plasmids. In total, 11 ratios with the respective plasmids’ concentration 
varying in 10% increments were probed (one Env ranging from 100% to 0%, 
the second ranging from 0% to 100% in the same cotransfection). The fol-
lowing Env genes were studied: Env’s that carry the epitope of the V3 loop 
mAbs 19b and 1-79 (JR-FL*WT, JR-FL*V1V2, and NL4-3WT_JR-FLV3) 
and Env’s that do not carry the 19b epitope (NL4-3WT, NL4-3V1V2, and 
JR-FL*V1V2_V3NL4-3). The following pairs were investigated: (a) JR-
FL*WT with NL4-3V1V2 (Fig. 5 C), (b) NL4-3WT_JR-FLV3 with NL4-
3V1V2 (Fig. 5 D), (c) JR-FL*V1V2_V3NL4-3 with JR-FL*WT (Fig. 5 E), 
(d) NL4-3WT with JR-FL*V1V2 (Fig. 6 C), and (e) JR-FL*WT with 
JR-FL*V1V2 (Fig. 7 C).
Cells were detached 48 h after transfection using PBS, 1% FCS, and 10 mM 
EDTA, and V3 loop accessibility was studied by monitoring the binding 
efficiency of the V3 loop mAbs 19b or 1-79 to the heterogeneous Env 
proteins expressed on the cells’ surface. As control for equivalent Env ex-
pression of the heterotrimer, binding efficiency of the carbohydrate-specific 
mAb 2G12, which binds to all probed WT and Env mutants with compa-
rable efficiency, was assessed in all experiments (Fig. S2). Stainings were per-
formed with mAbs 19b and 1-79 and biotinylated mAb 2G12, and bound 
antibody was detected using Cy5-conjugated F(ab)2 goat anti–human IgG 
(Jackson ImmunoResearch Laboratories, Inc.) and streptavidin-APC 
(BioLegend), respectively. Viability stain propidium iodide (Invitrogen) was 
added to all samples 10 min before acquisition, and dead cells were excluded 
from analysis. Samples were acquired on a CyAn ADP Analyzer (Beckman 
Counter) and analyzed using FlowJo software (Tree Star). The highest MFI 
measured in each experiment was set as the maximum fluorescence level 
(100%), and measured MFI signals were normalized to the percentage of 
maximum fluorescence (% max).
Statistical analysis and data processing. All 50% neutralization, inhibi-
tion, or binding doses were determined by fitting a sigmoid dose–response 
curve with a variable slope through the pooled data of two to three indepen-
dent assays. Error bars indicate the 95% confidence interval calculated by 
Prism software. Fold increases in plasma neutralization and binding activity 
refer to the difference between median activity of the 83 plasma samples 
against WT and V1V2-deleted Env’s (Fig. 1). One-way analysis of variance 
with post-tests Tukey’s multiple comparison and Newman Keuls was used 
to test whether the mean neutralization activity of the 83 patients’ plasma 
measured against NL4-3V1V2 is significantly different from the other V1V2 
viruses. The same test was used to compare the datasets after V3 peptide 
would cause fluctuations in the expression levels of monomers and dimers but 
also the total Env content of the cell as a substantial proportion of the Env pro-
teins will be released and thus lost for analysis. In the event that heterotrimers 
dissociate at a higher frequency than homotrimers, total Env expression levels 
should be lower at those Env ratios where the highest heterotrimer formation is 
to be expected (fbs = 0.5). We have controlled for Env expression in each indi-
vidual experiment by assessing the capacity of mAb 2G12 to bind to cell surface–
expressed Env’s. This mAb recognizes monomeric, dimeric, and trimeric gp120 
and is largely unaffected by the presence of V1V2 and the mutations in V3 stud-
ied here. Based on 2G12 reactivity, we were able to exclude the possibility that 
the studied heterotrimers are inherently instable and promote spontaneous shed-
ding and thus monomeric and dimeric gp120 formation. Env concentration was 
comparable at all Env ratios studied. Should a heterotrimer be instable, total Env 
content as measured by 2G12 would be lower in cell populations that contain a 
higher heterotrimer content (e.g., fbs = 0.5).
However, as some degree of spontaneous shedding will occur regardless 
of what specific Env is studied, we had to evaluate the effect of antibody 
binding to gp120 monomers and dimers in our assay system. To assess the 
potential impact of monomers and dimers on our prediction of the normal-
ized MFI, we assumed that the total number of gp120 monomers and dimers 
expressed on a transfected cell is the same for all investigated cell populations. 
For setup 1 and 2, we assumed that one antibody binds to a binding-sensitive 
Env monomer, one antibody binds to a heterodimer (consisting of one 
V3 loop–sensitive and one resistant Env), and two antibodies bind to a homo-
dimer consisting of two binding sensitive Env’s. In the case of setup 3, two anti-
bodies are assumed to bind to heterotrimers. Monomers are expressed at 
a rate a, and dimers of either type are expressed at a rate b. Under these 
assumptions, we simply have to add the terms afbs for antibodies binding to 
monomers and a term for the binding to dimers, which, for setup 1 and 2, is 
b(2fbs(1  fbs) + 2fbs2), or, for setup 3, b(4fbs(1  fbs) + 2fbs2), to the expressions 
in Table I. Upon simplification, we derived the following formulas for setup 
1 and 2 under the consideration of monomer/dimer binding (Table III).
The parameter c = a + 2b denotes the fraction of antibodies bound to 
monomers and dimers. If the neighboring protection scenario holds true, 
c can be estimated from the normalized MFI in setup 1 at the point fbs = 1.
Experimentally probing self and neighboring protection modes of 
the V1V2 loop. 293-T cells seeded in 12-well tissue culture plates were 
transfected with 1.6 µg of the respective HIV Env–encoding plasmids and 
0.4 µg of the rev-encoding plasmid pCMV-rev using jetPEI (Polyplus Trans-
fection; Chemie Brunschwig AG) according to the manufacturer’s instruction. 
To generate virions bearing heterogeneous Env trimers, two different 
Table II. Mathematical models for the number of antibodies bound per trimer under the consideration of Env protein 
segregation
Setup Neighboring protection Self protection
1 1 × P1 + 1 × P2 0
2 1 × P2 + 3 × P3 1 × P1 + 2 × P2 + 3 × P3
3 1 × P1 + 2 × P2 + 3 × P3 1 × P1 + 2 × P2 + 3 × P3
Table III. Mathematical models for the number of antibodies bound per trimer under the consideration  
of monomer/dimer binding
Setup Neighboring protection Self protection
1
3 1 3 1
2 2f f f f cfbs bs bs bs bs-( ) + -( )+
cfbs
2 1 3 1 32 3´ -( )+ ´ +f f f cfbs bs bs bs 1 3 1 2 3 1 32 2 3´ -( ) + ´ -( )+ ´ +f f f f f cfbs bs bs bs bs bs
3
1 3 1 2 3 1 3 4 2
2 2 3 2´ -( ) + ´ -( )+ ´ + + -f f f f f af bf bfD D D D D D D D 1 3 1 2 3 1 3 4 2
2 2 3 2´ -( ) + ´ -( )+ ´ + + -f f f f f af bf bfD D D D D D D D
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